Ero1 and redox homeostasis in the endoplasmic reticulum  by Sevier, Carolyn S. & Kaiser, Chris A.
Available online at www.sciencedirect.com
Biochimica et Biophysica Acta 1783 (2008) 549–556
www.elsevier.com/locate/bbamcrReview
Ero1 and redox homeostasis in the endoplasmic reticulum
Carolyn S. Sevier, Chris A. Kaiser ⁎
Department of Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
Received 15 September 2007; received in revised form 1 December 2007; accepted 13 December 2007
Available online 23 December 2007
Abstract
Living cells must be able to respond to physiological and environmental fluctuations that threaten cell function and viability. A cellular event
prone to disruption by a wide variety of internal and external perturbations is protein folding. To ensure protein folding can proceed under a range of
conditions, the cell has evolved transcriptional, translational, and posttranslational signaling pathways to maintain folding homeostasis during cell
stress. This review will focus on oxidative protein folding in the endoplasmic reticulum (ER) and will discuss the features of the main facilitator of
biosynthetic disulfide bond formation, Ero1. Ero1 plays an essential role in setting the redox potential in the ER and regulation of Ero1 activity is
central to maintain redox homeostasis and proper ER folding activity.
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As the first organelle in the secretory pathway, the en-
doplasmic reticulum (ER) is dedicated to the folding and as-
sembly of secretory proteins and is enriched for enzymes
that assist several steps in the folding process [for reviews see
[1,2–4]]. Molecular chaperones act as folding catalysts, for the
initial transition from unfolded polypeptide to tertiary structure,
and later in quality control, to ensure that only native folded
proteins exit the ER into the secretory pathway. Enzymatic
modification of newly synthesized polypeptides, including
carbohydrate addition and disulfide bridge formation, also play
an important role in protein folding and quality control. These
modifications promote long-term protein stability for folded
conformations and are an essential step in the folding process of
many secretory proteins.
Pharmacological or physiological disruption of ER folding
events leads to the buildup of unfolded polypeptides in the ER
lumen and ER stress. When the folding demand of the ER⁎ Corresponding author. Tel.: +1 617 253 9804; fax: +1 617 253 6622.
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doi:10.1016/j.bbamcr.2007.12.011surpasses the folding capacity of the ER, cells respond by
inducing the unfolded protein response (UPR) [5,6]. In this ER-
to-nucleus signaling pathway, sensors in the ER recognize
unfolded proteins and transmit information across the ER
membrane to activate downstream transcription factors, which
in turn control an extensive gene-expression program. Genes
induced by the UPR increase the ER folding capacity by
expanding the ER lumen and augmenting the complement of
folding chaperones and modifying enzymes. UPR induction
also enhances the removal of irreparably misfolded proteins
from the lumen by ER-associated degradation (ERAD). Pro-
longed UPR induction that does not reestablish homeostasis to
the ER folding capacity leads to apoptosis.
An ER folding step that is acutely sensitive to perturba-
tions of the lumenal ER environment is disulfide bond for-
mation. Oxidative protein folding depends upon the
maintenance of sufficiently oxidizing conditions within the
ER lumen. A too reducing ER environment is unfavorable to
disulfide bond formation [7]. Conversely, an overly oxidizing
ER can lead to trapping of polypeptides in misoxidized
misfolded states [8]. The membrane associated flavoprotein
Ero1 is a significant source of oxidizing equivalents for the
ER lumen and thus is responsible for setting the ER oxidation
Fig. 1. Ero1 structure. Structure of yeast Ero1 residues 56–424 [29]. Cysteine
side chains are represented as green and yellow spheres and the FAD cofactor is
drawn as orange sticks. The polypeptide domain (residues 90–175) containing
the shuttle cysteine pair is colored red. Note the two regulatory disulfides that
contain one cysteine on the red region (Cys90 and Cys150) and one cysteine on
the helical core (Cys295 and Cys349).
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formation (by addition of exogenous reductant) leads to UPR-
mediated induction of ERO1 [9–11]. We have recently shown
that both oxidative and reductive shifts in the ER environment
are counteracted also by posttranslational regulation of Ero1
activity through two non-catalytic “regulatory” cysteine pairs
[12]. We have proposed that the modulation of Ero1 activity
(by changes in the redox state of its regulatory cysteine pairs)
is part of a homeostatic feedback system in the ER that allows
the cell to rapidly offset potentially detrimental fluctuations in
the ER redox environment and maintain conditions conducive
for oxidative protein folding [12]. Herein we will discuss
Ero1 function in the cell and the future directions and
questions relating to the regulation of Ero1 activity and ER
homeostasis.
2. Ero1 catalyzes disulfide bond formation in the ER
Ero1 (ER oxidoreductin) is a glycosylated flavoenzyme
tightly associated with the lumenal face of the ER membrane.
ERO1 was characterized first genetically in two parallel screens
in Saccharomyces cerevisiae [9,10]. Loss-of-function Ero1
mutants in yeast fail to provide oxidizing equivalents to the ER
for disulfide bond formation and consequently accumulate
reduced misfolded proteins in the ER [9,10]. Currently, Ero1
proteins have been characterized in several additional organ-
isms including Homo sapiens [13,14], Caenorhabditis elegans
[15], Arabadopsis thaliana [16], and Schizosaccharomyces
pombe [17]. Not surprisingly, the most extensive studies on
Ero1 have focused on S. cerevisiae and H. sapiens.
Ero1 and the thioredoxin-like protein protein disulfide
isomerase (PDI) form the major pathway for protein disulfide
bond formation in the eukaryotic ER. Ero1 influences protein
oxidation by coupling the oxidizing power of molecular
oxygen and its flavin cofactor to generate disulfide bonds [18–
20]. These disulfides are transferred from Ero1 to the soluble
disulfide-carrier PDI, which directly transfers its disulfides to
folding secretory proteins [21–23]. Transfer of electrons from
substrate proteins to PDI, and from PDI to Ero1, proceeds as a
series of direct thiol-disulfide exchange reactions [20–25]. In
vitro reconstitution of the Ero1-PDI-substrate oxidation system
with purified components solidified the capability and
sufficiency of this pathway for protein disulfide generation
[20].
Despite an overall conservation of the Ero1-PDI pathway
for disulfide bond formation among eukaryotes, a striking
disparity between H. sapiens and S. cerevisiae systems is that
human cells contain two Ero1 paralogs, Ero1-Lα and Ero1-Lβ
(S. cerevisiae Ero1-like) [13,14] while S. cerevisiae encodes a
single Ero1 [9,10]. Intriguingly, the presence of one or two
ERO1 genes in an individual organism is not simply predicted
by evolutionary criteria. In general, vertebrates have two ERO1
while invertebrates and fungi contain a single ERO1. However,
exceptions do exist; two Ero1 proteins have been described in
S. pombe (fungi) [17] and a BLAST search of Tribolium
castaneum (flour beetle) reveals two Ero1-like proteins (acces-
sion numbers: XP_967561 and XP_972037). The significanceof two Ero1 proteins encoded in a single genome is not clear and
currently no major differences in redox activities or substrate
interactions have been described between the characterized
human paralogs. Both human proteins are functional homologs
of S. cerevisiae Ero1 and can complement the phenotypic
defects of the temperature-sensitive ero1-1 yeast strain [13,14].
Human ERO1s show distinct transcriptional regulation and it is
possible that more than one ERO1 allows cells to modulate the
oxidizing potential of the ER under specific stress conditions
[14,26]. Similarly, plant ERO1s (AEROs) appear to possess
different transcriptional regulatory elements, although transcrip-
tional induction of AERO1 and AERO2 under stress conditions
has not been analyzed [16]. Distinct tissue distribution for
human Ero1-Lα and Ero1-Lβ also suggests the potential for
tissue specific oxidation pathways [14].
3. Ero1 uses an inter-cysteine relay to transfer disulfides to
substrates
Ero1 uses two catalytic cysteine pairs (four cysteines) to
oxidize PDI: the “active-site” and “shuttle” cysteines [27,28].
The active-site cysteine pair is positioned adjacent to the redox
active isoalloxazine moiety of the flavin cofactor, which is
cradled by four antiparallel alpha-helices [29] (Fig. 1). The
shuttle cysteine pair, which comes in close proximity to the
active-site cysteines, is located in a flexible polypeptide loop
that rests on the surface of the protein and lacks significant
secondary structure [29] (Fig. 1). The catalytic cycle of Ero1
involves direct oxidation of PDI by the shuttle cysteine pair, and
re-oxidation of the reduced shuttle cysteines through internal
dithiol-disulfide exchange with the active site [24,28] (Fig. 2).
The active-site cysteines of Ero1 are re-oxidized by transfer of
their electrons to the flavin cofactor and molecular oxygen
(producing hydrogen peroxide) [18–20].
Movement of the Ero1 polypeptide loop containing the
shuttle cysteines appears to be part of the Ero1 catalytic mecha-
nism, helping to shuttle electrons from the redox-active
Fig. 2. Ero1 catalytic mechanism. Cartoon-depiction of Ero1 shows the shuttle
cysteines (red region), active-site cysteines (black), and FAD cofactor (orange).
Thin arrows reflect electron flow.
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in Ero1. Two crystal forms of Ero1 show two discrete confor-
mations for the loop containing the shuttle cysteines, signifying
the flexibility of this region of Ero1 in solution [29]. A catalytic
mechanism involving electron shuttling between two cysteine
pairs allows for specific oxidation of PDI and prevents the
indiscriminate oxidation of ER proteins and small molecules by
controlling access to the very oxidizing FAD-cysteine active-site
couple in Ero1 [24]. The lack of secondary structure in the Ero1
polypeptide loop containing the shuttle cysteines may facilitate
the association of Ero1 with PDI by mimicking PDI's natural
substrate, an unfolded polypeptide.
4. Two non-catalytic cysteine pairs regulate Ero1 activity
Ero1 activity can be controlled through the redox state of two
non-essential “regulatory” cysteine pairs in Ero1. These regu-
latory disulfides connect the extended polypeptide loop domain
(containing the shuttle cysteines) to the surface of the helicalFig. 3. Posttranslational Ero1 regulation. The catalytic cysteines are shown as bla
the shuttle cysteines is colored red. The regulatory cysteines are depicted as white “S
By tethering the non-helical loop domain to the protein core, formation of the reg
Ero1 activity under oxidizing ER conditions. When the regulatory disulfides are red
oxidation.core of Ero1 (Fig. 1). The positioning of these non-catalytic
cysteines, combined with the observed flexibility for the poly-
peptide region surrounding the shuttle cysteines [29], has led us
to propose that the regulatory cysteines pairs control the range
of motion for the shuttle-cysteine-containing loop region to
modulate Ero1 function [12]. Under oxidizing ER conditions,
formation of the regulatory disulfides appears to tether the loop
to the helical core, which restricts the movement of the shuttle
cysteines and limits the ability of Ero1 to shuttle disulfides to
PDI (Fig. 3). Under reducing ER conditions, reduction of the
regulatory disulfides likely enhances the range of motion for
the polypeptide loop domain and increases Ero1 activity
(Fig. 3). We have suggested that the ability of the regulatory
cysteines to sense the ER oxidation state and correspondingly
alter Ero1 activity serves to offset fluctuations in the ER redox
environment [12].
Ero1 activity can be decoupled from its regulation in vivo by
replacing one of the two regulatory cysteine pairs with alanine
(Ero1-C150A-C295A) [12]. When this allele is transformed
into yeast the second regulatory disulfide (Cys90-Cys349)
becomes reduced, effectively creating a constitutively active,
deregulated Ero1. Overexpression of this mutant allele inhi-
bits yeast growth, which is likely a result of hyperoxidation
of the ER and increased production of reactive oxygen species
(hydrogen peroxide) in the ER [12,15,30]. The ability of a
reducing agent (DTT) to alleviate the growth defect from Ero1-
C150A-C295A overexpression confirmed that growth in-
hibition is a consequence of increased Ero1 activity and ER
oxidation [12].
Currently, redox regulation of Ero1 has been demonstrated
only for S. cerevisiae Ero1. However, the presence of multiple
cysteine residues, in addition to the catalytic cysteines, in all
Ero1 homologs suggests the capacity for Ero1 regulation exists
in different organisms. A positional equivalent for one (of the
two) regulatory disulfides in yeast Ero1 (Cys90-Cys349) is
present in almost all Ero1 homologs and likely forms a con-
served regulatory disulfide bond; only one Ero1-like proteinck ovals with white text and the extended non-helical polypeptide containing
S”-containing ovals when oxidized and black thiol “SH” groups when reduced.
ulatory disulfides may restrict mobility of the shuttle cysteines and decrease
uced, active Ero1 uses molecular oxygen to facilitate PDI and substrate protein
Fig. 4. Cysteines in yeast and human Ero1s. S. cerevisiae (Sc) Ero1 is depicted as a gray rectangle with lighter grey regions reflecting sequence absent in the
crystal structure. Black denotes the four helices that form the catalytic core, red marks the extended loop polypeptide (residues 80–180), filled circles note
cysteines (labeled with residue numbers), and solid lines show the cysteine connectivity from the crystal structure of yeast Ero1 [29]. Green circles reflect
catalytic cysteines in S. cerevisiae and H. sapiens (Hs) Ero1, yellow circles note cysteines demonstrated to be regulatory in Sc Ero1 and predicted by
conservation to be regulatory in Hs Ero1. Dotted lines indicated cysteines positionally conserved between Sc and Hs Ero1s. Arrows note three cysteines in
the predicted loop region for Hs Ero1 (L1–3) and two cysteines in the core domain (C4–5) that have the potential to form regulatory loop-to-core disulfide
bonds.
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cuniculi lacks a positional equivalent for the yeast disulfide
(accession number NP_584701). The second yeast Ero1
regulatory disulfide (Cys150-Cys295) is less conserved. How-
ever, human Ero1-Lα migrates as three distinct redox isoforms
on non-reducing gels (R, Ox1, and Ox2), which is consistent
with the presence of two regulated loop-to-core disulfides
[21,27]. There are three cysteines in the loop and two cysteines
in the helical core region of Ero1-Lα that could form loop-to-
core regulatory disulfides (Fig. 4), although when the Ero1-Lα
Cys208 and Cys241) and the loop cysteines appear to be too
distant in space to form a disulfide bond. It is also possible
that three redox forms for Ero1-Lα observed by SDS-PAGE
reflect reduction of the Cys90-Cys349 equivalent (Cys85-
Cys391) and/or reduction of an internal loop disulfide (e.g.
between CysCys131 and Cys166, analogous to yeast Cys143-
Cys166), which may extend the range of motion of the loop
region. Mass spectrometry showed that the internal loop
disulfide Cys143-Cys166 is reduced in activated yeast Ero1
[12]; due to the short-range nature of this disulfide, its reduction
does not significantly impact the mobility of yeast Ero1 on
SDS-PAGE. Intriguingly, Ero1-Lα and Ero1-Lβ have the
potential for unique regulatory disulfides based on an additional
cysteine in the helical core domain of Ero1-Lβ that is absent in
Ero1-Lα (Fig. 4, arrow C5).
5. Glutathione impacts Ero1 activity in the ER
Initial insight into the requirements for Ero1 regulatory
disulfide reduction came with the observed impact of cellular
glutathione levels on Ero1 activation in S. cerevisiae. Lowering
cellular glutathione levels by treatment with an inhibitor
of glutathione synthesis (buthionine sulfoxide) alleviates the
growth defect from Ero1-C150A-C295A overexpression [12].
Examination of the redox state of Ero1-C150A-C295A in cells
with lowered glutathione levels revealed that mutant Ero1 wasin the oxidized inactive form [12]. These data suggest that
glutathione normally plays a role in the reduction and activation
of Ero1. Consistent with this interpretation, reduced glutathione
has also been shown to influence transition between the Ox2
and Ox1 redox forms of human Ero1-Lα [31]. A role for
glutathione depletion in alleviating oxidative stress from active
Ero1 was initially unexpected based on glutathione's character-
ized role as an antagonist of the Ero1-PDI oxidation pathway
[31,32]. However, the inactivation of the hyperactive Ero1
mutant when glutathione is depleted prevents ER hyperoxida-
tion, which appears to outweigh any potential negative impact
of a diminished glutathione redox buffer [12]. As glutathione is
a poor substrate and activator of purified Ero1 in vitro
[12,20,24], it seems unlikely that glutathione is a direct
reductant of the regulatory disulfides. Instead, glutathione
may affect the redox state of the regulatory disulfides indirectly
by maintaining a direct reductant (perhaps PDI and/or related
proteins) in a reduced form.
Activation of wild-type Ero1 proceeds as two sequential
steps: (1) reduction of Cys150-Cys295 and (2) reduction of
Cys90-Cys349 [12]. Cellular glutathione levels appear to dif-
ferentially affect these two steps; step 2 appears to be dependent
on cellular glutathione levels, whereas step 1 is independent of
glutathione. A significant fraction of wild-type Ero1 is oxidized
and inactive under standard growth conditions, indicating that
normal levels of glutathione are insufficient to reduce Cys150-
Cys295 [12]. In contrast, normal cellular glutathione levels
cause almost complete reduction of Cys90-Cys349 in a mutant
that can not form the Cys150-Cys295 disulfide bond (Ero1-
C150A-C295A) [12]. Considering these data, we anticipate that
Ero1 activation is initiated by a glutathione-independent redox
factor that reduces Cys150-Cys295. In vitro this step can be
facilitated by a PDI-like protein [12], although the physiolo-
gical reductant of Cys150-Cys295 in vivo remains to be
identified. Reduction of Cys150-Cys295 likely triggers struc-
tural changes in the regulatory loop, exposing Cys90-Cys349 to
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active enzyme. Use of multiple molecules to modulate the
redox state of the two regulatory disulfides in Ero1 may ensure
that Ero1 activation only occurs during defined ER redox
conditions.
Increased Ero1 activity in the ER enhances glutathione
oxidation (GSSG formation) [12,32] and also impacts glu-
tathione synthesis [31]. It has been suggested that GSSG for-
mation in the ER reflects glutathione-mediated reduction of
(misoxidized) substrate proteins and/or PDI [20,31–34].
Considering the relationship between glutathione and Ero1 in
the ER, it may seem incongruous that Ero1 activity would both
generate ROS and deplete a scavenger of ROS, reduced glu-
tathione. Increased glutathione synthesis under oxidative stress
may allow for ROS inactivation, even in the presence of an
increased rate of glutathione oxidation. Consistent with a role
for glutathione in ROS elimination, addition of exogenous
glutathione or cysteine (a glutathione precursor) prevented ROS
accumulation under conditions that normally lead to enhanced
ROS levels in the ER lumen [15,30].
6. Ero1 regulation influences ER physiology
It is interesting to consider the potential implications for the
regulation of Ero1 activity on additional redox-active species in
the ER. The redox reaction catalyzed by a given oxidoreductase
(oxidation, reduction, or isomerization) is determined by the
redox state of its active-site cysteine pairs. An inability to
regulate Ero1 activity may lead to unwanted oxidation of
reductases or isomerases in the ER, which is likely to negatively
impact ER physiology by preventing reduction/isomerization of
misoxidized substrates. Reduction of protein disulfides has been
shown to precede dislocation and degradation of misfolded
proteins targeted for ER-associated degradation [35,36] and ER
hyperoxidation may also prevent the reductase activity
necessary to clear misfolded ERAD substrates. Conversely,
modulation of the redox state and activity of PDI through
regulation of Ero1 activity may be beneficial to cells and
facilitate the response and recovery from fluctuations in the ER
redox environment. Under steady-state conditions, approxi-
mately 70% of yeast PDI active sites are oxidized [37].
Accumulation of more PDI in the reduced form when Ero1
function is compromised could augment the amount of PDI
available as a reductase or isomerase and promote the
reshuffling of nonnative disulfide bonds accumulated during
oxidative stress. The enhanced chaperone activity of reduced
PDI may also help alleviate the load of misoxidized proteins by
stimulating their unfolding, dislocation, and degradation [38].
The potential for regulation of PDI redox activity by
feedback regulation of Ero1 has interesting evolutionary
implications on the divergence of oxidative protein folding
pathways from bacteria to eukaryotes. In bacteria, two separate
pathways are used to maintain oxidized and reduced pools of
enzymes in the periplasmic space for protein oxidation and
isomerization [reviewed in [39,40]]. These competing oxidation
(DsbB-DsbA) and reduction/isomerization (DsbD-DsbC) path-
ways are kept distinct due to steric incompatibility of the solublePDI-like component of one pathway (DsbA or DsbC) and the
membrane-embedded component of the opposing pathway
(DsbB or DsbD) [41–43]. Regulation of Ero1 to control the
activity of PDI may provide a means for a single oxidoreductase
to catalyze both protein oxidation and reduction. A single
system centered upon PDI would explain why a dedicated
protein-based reduction pathway in the ER analogous to the
DsbD-DsbC system in the bacterial periplasm has not been
identified in eukaryotes.
7. Ero1's role in oxidative protein folding and ER stress
Ero1 activity generates one molecule of hydrogen peroxide
for each biosynthetic disulfide bond formed [18]. Correspond-
ingly, experiments in yeast and worms have implicated Ero1
activity in the accumulation of ROS in the ER of whole cells
[15,30]. An intriguing rough calculation estimates that Ero1
activity may be a significant cause of cellular ROS, especially in
cells with heavy secretory loads, accounting for up to 25% of
the ROS produced during protein synthesis [44]. Although Ero1
appears to be a major source of ER peroxides, the absence of
chronic oxidative stress suggests that the cell can cope with
peroxides formed during routine protein folding. When ROS
production exceeds the capacity of these antioxidant defense
systems, it is anticipated that cellular redox homeostasis will be
altered and oxidative stress ensue.
Controlling the production of amino acids for protein and
glutathione biosynthesis appears to be one means to protect
cells against oxidative stress and avert cellular damage from
ROS accumulation. In multicellular eukaryotes, accumulation
of misfolded proteins in the ER leads the stress-activated kinase
PERK to phosphorylate the alpha subunit of the translation
initiation factor 2 (eIF2α), which inhibits general protein
synthesis and enhances the translation and expression of the
transcription factor ATF4 [reviewed in [5]]. Treating mouse or
worm cells lacking PERK with agents that perturb protein
folding in the ER (e.g. tunicamycin) leads these cells to
accumulate ROS [15]. ROS buildup in the ER under these
conditions depends on oxidative protein folding and Ero1
activity [15]. PERK is thought to defend against Ero1-mediated
oxidative stress through ATF4-mediated activation of antiox-
idant responses and cysteine sufficiency and accordingly ROS
levels abate with the exogenous addition of cysteine (oxidized
cysteine, which is rapidly converted to reduced cysteine after
cellular import) [15]. PERK-mediated translation attenuation
may protect cells also against ROS accumulation by decreasing
the quantity of proteins undergoing oxidative protein folding. In
addition, it is possible that inactivation of the PERK signaling
cascade interferes with feedback regulation of Ero1 activity,
leading to increased Ero1 activity and ROS production.
However, increased levels of ROS have not been detected in
yeast overexpressing deregulated Ero1 (Ero1-C150A-C295A)
[12], suggesting that deregulation of Ero1 activity alone may
not be sufficient to explain ROS accumulation in tunicamycin-
treated PERK mutants.
Fungi do not contain PERK. However, yeast does contain an
ATF4-like transcription factor Gcn4 that is activated by the
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Gcn4 is responsible for activating approximately one-third of
the genes induced by treatment with the alkylating agent methyl
methanesulfonate (MMS), suggesting a potential role for Gcn4
in the response to oxidative stress [46]. Gcn4 has also been
shown to collaborate with Hac1 to stimulate transcriptional
induction of UPR genes during ER stress [47].
ER-associated degradation (ERAD) also appears to prevent
ROS buildup by clearing misfolded proteins from the ER and
thereby preventing persistent cycles of futile oxidation by Ero1.
In yeast, increased ROS levels in the ER have been observed by
stressing the ER folding machinery with dual hits in the
oxidative folding and degradation systems; overexpression of a
protein prone to misfolding (CPY⁎) in a strain unable to clear
the nonnative protein from the ER lumen due to a mutation in
the ERAD system (erv29Δ) leads to prolonged activation of the
UPR and ROS production [30]. Here, it has been suggested that
accumulation of toxic levels of ROS is caused by the futile
cycling of the Ero1-PDI oxidation cycle along with the
depletion of the ROS scavenger glutathione [30]. Intriguingly,
preventing induction of the UPR (ire1Δ or hac1Δ) in the CPY⁎
erv29Δ strain alleviates ROS accumulation [30], suggesting
that UPR activation may exacerbate rather than alleviate
oxidative folding stress.
8. Ero1 function in oxidative stress and disease
Cells expected to be particularly susceptible to changes in
Ero1 activity include specialized secretory cells that express
large quantities of disulfide-bonded proteins. Correspondingly,
Ero1 could potentially have profound effects on the develop-
ment of diabetes by impacting the folding and secretion of
insulin by pancreatic β-cells. Changes in the redox status of
the ER and Ero1 have been observed in (streptozotocin-
induced) diabetic rats [48]. Intriguingly while an overall
reductive shift was observed in diabetic rat microsomes, Ero1
was observed in a more oxidized state [48], which could reflect
oxidation of the regulatory disulfides and Ero1 inactivation.
Conversely, increased Ero1 activity and/or inefficient inactiva-
tion may also lead to aberrant β−cell physiology. In the Akita
mouse, a spontaneous cysteine-to-tyrosine (C96Y) mutation in
the insulin-2 gene (Ins-2) precludes formation of one of two
disulfide bonds and causes early-onset diabetes and decreased
β−cell mass [49]. Retention of mutant malfolded insulin-2
protein in the ER perturbs β−cell function, which could be due
to increased Ero1 activity and ROS production caused by
repeated cycles of futile disulfide formation [30,50]. Ero1 has
been suggested also to have a role in both oxidative folding
and release of thiol-mediated ER retention of the insulin-
sensitizing hormone adiponectin [51,52]. Conceivably,
decreased levels of active Ero1 could inhibit adiponectin
secretion and contribute to the lower plasma levels of
adiponectin in humans and animals with obesity and insulin-
resistant diabetes.
The essential role for Ero1 in oxidative folding and cell
viability makes Ero1 a possible target for pharmacological
intervention in disease. ERO1 is one of eight genes associatedwith poor prognosis for lung adenocarcinomas [53]. Ero1
activity in hypoxic tumor cells improves protein secretion of the
proangiogenic factor VEGF and targeted inhibition of Ero1
activity may inhibit tumor growth by preventing VEGF-driven
angiogenesis. [54]. Neonatal exposure to sublethal hypoxic
conditions confers neuroprotection to later hypoxic insult,
which is thought to be a result of induction of vasoregulatory
mediators (including ERO1) that improve vascular ability to
maintain blood flow to the brain during later hypoxic challenges
[55]. Ability to recreate this neuroprotective pathway could
prevent ischemic neuronal cell death, which is a principal neu-
ropathological feature of stroke.
9. Conclusions
Since the first identification of Ero1 approximately ten years
ago, significant progress has been made toward understanding
the mechanisms used by Ero1 to facilitate disulfide bond
formation. Recognition of Ero1 as a central player in the
maintenance of cellular redox homeostasis provides a focal
point for future studies relating to how redox regulation in the
ER is coupled with cellular physiology. Elucidating the role for
Ero1 activity and regulation in both basic cell growth and
pathological conditions is likely to have significant impact for
understanding the role of Ero1 and oxidative stress in health and
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